Reducing Malaria to its Constituent Parts

FIRST BITE:Courtesy of CDC/Jim GathanyFemale Anopheles gambiae mosquito feeding.A decade ago, scientists around the world recognized that despite malaria's tremendous disease burden, research on the topic had stagnated. With funding at low levels, robust molecular biology tools numbered few. Today, genome sequences for Plasmodium falciparum, the parasite causing malaria, and for Anopheles gambiae, the mosquito that spreads it, have already fundamentally changed the research landscape. Plasmodium

Written byEugene Russo
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Courtesy of CDC/Jim Gathany

Female Anopheles gambiae mosquito feeding.

A decade ago, scientists around the world recognized that despite malaria's tremendous disease burden, research on the topic had stagnated. With funding at low levels, robust molecular biology tools numbered few. Today, genome sequences for Plasmodium falciparum, the parasite causing malaria, and for Anopheles gambiae, the mosquito that spreads it, have already fundamentally changed the research landscape. Plasmodium is now the subject of more grant applications than any other parasite, according to Michael Gottlieb, chief of the parasitology and international programs branch at the National Institute of Allergy and Infectious Diseases, a funder for both genome projects. The Anophleles data have been slower to influence, Gottlieb says: "It's taking more time for it to have the same level of impact, but it's coming."

The P. falciparum genome-sequencing project, started in 1996, was burdened with technological hurdles and political issues. A draft ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies